Blank Rome Represents Reaction Biology Corporation in Growth Investment from Cobepa
A Blank Rome team represented Reaction Biology Corporation, an industry-leading provider of drug discovery services, in a significant investment from Cobepa, an international private equity firm, to fuel the company’s continued growth and service line expansion. The transaction closed on March 15, 2022.
This investment by Cobepa provides capital and resources to support the growth of Reaction Biology Corporation, which will focus on strategically expanding its capabilities and geographic footprint as well as cultivating key talent to enhance the company’s ability to better serve the needs of its biopharmaceutical customers and provider and patient communities.
For more information on this transaction, please read Reaction Biology Announces Closing of Growth Investment from Cobepa and Chief Executive Officer Transition (PR Newswire, March 16, 2022).
The Blank Rome team was led by Frank Dehel, Emma Pachon, and Tyler Hill, with significant support from Jourdan Garvey, Andrew Rudolph, Jeffrey M. Rosenfeld, David Gilbert, Stephen Zumbrun, and Dan Morris, as well as assistance from Barry Friedman, George Boggs, Riley Bauer, Stephanie Gantman Kaplan, Yelena Barychev, and Ivy Shapiro.